Arcus Biosciences (RCUS) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $43.00 from $41.00 | Aug 6, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $26.00 from $23.00 | Aug 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 from $32.00 | Jul 20, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $46.00 | Jun 4, 2026 |
| Truist Securities | Initiated Coverage | Buy | $35.00 from $30.00 | May 18, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $22.00 from $20.00 | May 11, 2026 |
| Goldman Sachs | Maintained | Buy | $34.00 from $30.00 | May 7, 2026 |
| Wedbush | Maintained | Outperform | $41.00 from $37.00 | Apr 2, 2026 |
| Citigroup | Maintained | Buy | $45.00 from $44.00 | Mar 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $32.00 | Mar 2, 2026 |
| Leerink Partners | Maintained | Outperform | $49.00 from $36.00 | Mar 2, 2026 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $23.00 from $30.00 | Feb 12, 2026 |
| Goldman Sachs | Upgraded | Neutral → Buy | $28.00 from $16.00 | Jan 13, 2026 |
| Morgan Stanley | Downgraded | Overweight → Equal-Weight | $20.00 from $23.00 | Jan 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $32.00 from $28.00 | Dec 12, 2025 |
| B of A Securities | Maintained | Neutral | $26.00 from $17.00 | Nov 28, 2025 |
| Goldman Sachs | Maintained | Neutral | $16.00 from $14.00 | Oct 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $28.00 from $24.00 | Oct 29, 2025 |
| Citigroup | Maintained | Buy | $56.00 from $54.00 | Oct 29, 2025 |
| Wells Fargo | Maintained | Overweight | $29.00 from $25.00 | Oct 20, 2025 |
Frequently asked questions
What is the price target for RCUS stock?
The average 12-month analyst price target for Arcus Biosciences (RCUS) is $40.00, with a high estimate of $46.00 and a low of $26.00, across 4 analysts.
Is RCUS a buy, sell, or hold?
Analysts covering Arcus Biosciences currently average a Buy rating: 9 buy, 3 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for RCUS?
The average price target of $40.00 implies 36.61% upside from the last price of $29.28.
What is the latest analyst rating on RCUS?
On Aug 6, 2026, Wedbush maintained Arcus Biosciences at Outperform with a price target of $43.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.